We’re a biotechnology company on a mission to develop therapies that will get patients with a heart attack to the hospital with open coronary arteries. We focus on developing pre-hospital therapies, because early action is crucial to preserve heart muscle. The longer a coronary artery is closed, the more severe the damage to the heart. Starting treatment before patients reach the hospital, significantly improves the chances of a positive outcome. We’re developing zalunfiban; a prompt, potent, and predictable medication designed for treating patients with a heart attack before they reach the hospital. Zalunfiban has the potential to fulfil a significant unmet medical need in the pre-hospital phase of heart attack care. We’re currently running the CeleBrate trial: a pivotal Phase 3 prospective, blinded, randomized, placebo-controlled, international, multicenter, study designed to assess the safety and efficacy of a single subcutaneous injection of zalunfiban in patients with ST-segment elevation myocardial infarction in the pre-hospital setting.
